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Introduction
By September 1, 2020 the coronavirus disease – 19 
(COVID-19) pandemic has resulted in more than 25 mil-
lion confirmed cases and more than 850000 deaths [1]. The 
predominant clinical presentations are related to the respi-
ratory system; however, neurological manifestations are rec-
ognized increasingly. These features are determined by the 
effects of a combination of direct viral infection, inflamma-
tion of the structures of the nervous system and vasculature, 
nonspecific complications of systemic disease, which can be 
para-infectious or post-infectious [2].
Transverse myelitis (TM) is a focal disorder of the spinal 
cord presenting in acute or subacute manner (hours/days) 
resulting in motor, sensory, and autonomic dysfunction of 
varying degrees of expression depending on the type, loca-
tion and surface of the lesion longitudinally and transverse-
ly. The term longitudinally extensive transverse myelitis is 
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Abstract
Background: Immunocompromised status keeps on being a challenge for a physician, especially in the context of the coronavirus disease – 19 (COVID-19) 
pandemic.  The predominant clinical presentations are related to the respiratory system, but neurological manifestations are recognized increasingly. 
Cases of myelitis associated with the new coronavirus infection have already been published, but no cases of HIV-positive patients with myelitis and 
COVID-19 have been reported yet. 
Material and methods: This study described a clinical case of a human-immunodeficiency virus (HIV) – positive patient, who developed an acute 
transverse myelitis with confirmed SARS-CoV-2 infection. 
Results: Magnetic Resonance Imaging examination showed longitudinally extensive spinal cord abnormality, and laboratory tests confirmed SARS-CoV-2 
infection. The patient responded to methylprednisolone pulse therapy, followed by oral corticosteroids and therapeutic plasma exchange. 
Conclusions: Continuing pandemic and the expectation that a large part of the world population will be infected suggest that the number of patients with 
neurological manifestations could become large. Curious neurologic constellations can appear which complicate the diagnostic process and treatment 
in certain patients. 
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The possible causes of myelitis are as follows: infections 
(viruses, bacteria, fungi, and parasites), post-infectious or 
post-vaccination, paraneoplastic, demyelinating (multiple 
sclerosis (MS), neuromyelitis optica (NMO), acute dis-
seminated encephalomyelitis, other inflammatory disorders 
(neurosarcoidosis, systemic lupus erythematosus, Sjögren 
syndrome, Behcet’s disease), congestive edema due to du-
ral arteriovenous fistula, and tumor [3, 4]. TM may be id-
iopathic in 15-30% of cases. Post-infectious and idiopathic 
myelitis incidence varies between 1.3 - 8 cases / 1 million, 
but can reach 24.6 cases / million in patients with MS [5]. 
Recent case reports of myelitis associated with the new 
coronavirus infection were published, but the mechanism 
of spinal cord injury remains unclear [6, 7].
Human-immunodeficiency virus (HIV) causes spinal 
cord injury both by direct HIV virus invasion, presenting 
in vacuolar myelitis in most cases, as well as manifestations 
of opportunistic virus-induced infections (Herpes simplex 
virus (HSV), Cytomegalovirus (CMV), Epstein-Barr virus 
(EBV), Varicella Zoster virus, or bacteria (Mycobacterium 
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tuberculosis, Treponema pallidum), as well as due to vitamin 
B12 deficiency. Vacuolar myelopathy (VM) is symptomatic 
in 5-10% of acquired immune deficiency syndrome (AIDS) 
patients, shows a progressive evolution and is pathologically 
characterized by the presence of intralamellar white matter 
vacuoles in the posterior and lateral columns of the thoracic 
spinal cord [8].
SARS-CoV-2 causing the COVID-19 pandemic is prov-
en to be neurotropic and may affect the central and periph-
eral nervous system. The mechanism of the new type of 
coronavirus neuroinvasion has not yet been fully identified 
[2, 9]. Short- and long-term health effects for patients who 
have been infected have not yet been assessed. The changes 
induced by the new type of coronavirus in the coagulation 
status resulted in an impressive number of fatal thrombo-
embolic events, including the cerebral ones. Guillain-Barré 
syndrome reported in COVID-positive patients is explained 
as a possible parainfectious manifestation, whereas cases 
of necrotizing hemorrhagic meningoencephalitis, altered 
mental status, and respiratory distress syndrome are re-
ferred to both direct virus action on brain neurons, as well 
as cytokine storm syndrome [10, 11].
Material and methods
The present study reported a clinical case of a human-
immunodeficiency virus (HIV) – positive patient who devel-
oped an acute TM with confirmed SARS-CoV-2 infection.
Case report
A 27-year-old male, with known HIV infection for the 
past 1 year, treated with anti-retroviral therapy, was hospi-
talized on June 7, 2020 due to paresthesia and numbness in 
legs and in the right arm, paralysis in lower extremities, and 
bladder and bowel dysfunction (retention). All these symp-
toms developed quickly, reaching the nadir in 15 hours.
Clinical evaluation revealed normal cranial nerves 
function, spastic tetraparesis, with 4/4.5 Medical Research 
Council (MRC) in upper and 0.5/2MRC in lower extremiti-
es, Th7 superficial and C7 deep sensory level disturbances. 
The patient was subfebrile 37.5C without other systemic ab-
normalities. 
An extensive paraclinical workup was obtained. Routine 
laboratory data showed a slight general blood inflammato-
ry abnormalities (WBC 13.7 x109, ESR 14 mm/h) but with 
negative CRP. His CD4 count at admission was 310 cells/
µl, and viral load was less than 40 copies/ml. Cerebrospinal 
fluid (CSF) analysis was normal. Blood serology and CSF 
polymerase chain reaction (PCR) for HSV 1,2,6, CMV, EBV, 
Borrelia burgdorferi, Treponema pallidum, Toxoplasma 
gondii, Chlamydia trachomatis, Mycoplasma pneumoni-
ae, Ureaplasma urealyticum were negative. Autoimmune 
markers tests (autoantibodies ANA, ANCA), tumor marker 
tests (CA 19.9, Ca 15.3, PSA, CEA, Alpha Fetoprotein) and 
hepatitis viral serology all were negative. Thyroid function 
tests were normal. The first swab for SARS-CoV-2 at admis-
sion was negative. CSF oligoclonal bands (OCB) and serum 
anti-aquaporin-4 antibody (AQP4-IgG), anti-MOG anti-
bodies were negative. Vitamin B12, methylmalonic acid and 
angiotensin-converting enzyme levels were normal. Folic 
acid level test was 4.62 nmol/L (normal range 6.00-39.0). 
Brain MRI did not show any abnormalities. Spinal cord 
MRI revealed an extensive C4-Th5 lesion mainly in poste-
rior columns and right lateral column without gadolinium 
enhancement (fig. 1). 
The patient was treated with IV methylprednisolone 1g/
day for 5 days, followed by oral corticosteroids and five pro-
cedures of plasma exchanges. His condition improved with 
a significant reduction in paresis. Lung CT performed on 
the 19th day of illness showed slight patchy ground-glass 
opacity basal on the left side. No other typical symptoms 
for CoV-2 infection were noted. A repeated swab for SARS-
CoV-2 was positive, followed by negative COVID-19 PCR 
in the CSF. The 1-month follow-up spinal MRI did not re-
veal significant changes. 
Two-month follow-up revealed significant improvement 
of muscle strength allowing the patient to walk. Sphincter 
disturbances became less severe. At the same time, the CD4 
count dropped to less than 200 cells/µl.
Discussion
The presented case is unique for several reasons. All 
these circumstances – transverse myelitis, HIV infection 
and COVID-19 may be a random combination, as well as 
a range of three successive elements or an interrelation-
ship that influenced the onset of clinical signs and imaging 
changes. Normal CSF examination does not meet the TM 
diagnostic criteria [12]. Negative data for OCB and AQP4-
IgG, and normal brain imaging disclaim the most common 
demyelinating causes of TM-MS and NMO, but do not rule 
out a possible isolated clinical syndrome or NMO spectrum 
disorders.
Spinal cord injury presented in posterior and lateral col-
umns suggested a subacute combined degeneration due to 
vitamin B12 deficiency. Neurosyphilis and neurosarcoidosis 
were excluded by laboratory and imaging studies.
Despite the patient’s CD4 cells count that did not in-
dicate a severe degree of immunosuppression, the risk of 
opportunistic infections as a cause of myelitis had to be 
considered. However, the absence of CSF pleocytosis and 
normal infectious disease tests did not confirm this hypoth-
esis. HIV-associated spinal cord disease cannot be excluded, 
particularly vacuolar myelitis, which is slowly progressive 
and that predominantly occur at AIDS stage. The clinical 
examination usually demonstrates motor and sphincter dis-
orders, sensitive ataxia, though without a sensory level, as 
well as normal or discreetly modified MRI that often devel-
ops a simultaneous cognitive impairment [8].
The patient’s SARS-CoV-2 infection role is controversial. 
This could be an accidental co-infection during hospitaliza-
tion, a fact supported by the negative test results at admis-
sion and the lack of typical blood changes. At the same time, 
a false-negative result cannot be denied. High-dose corti-
costeroids therapy and plasma exchange might influence 
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the relatively benign course of SARS-CoV-2 pneumonia. 
Myelitis may resemble a direct virus injury, or a parainfec-
tious autoimmune process, as well due to molecular mim-
icry, the fact sustained by the positive response to cortico-
steroid therapy.
Conclusions
Continuing pandemic and the expectation that a large 
part of the world population will be infected, suggest that 
the number of patients with neurological manifestations 
could become greater. Curious neurologic constellations 
can appear which complicate the diagnostic process and 
treatment in certain patients. 
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Fig. 1. Sagittal and axial MRI shows the spinal cord segmental 
myelopathy area at C4-T5 level, ~15 cm in length, with a 
predominant involvement of the posterior and right lateral 
columns, without contrast uptake
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